A Phase 1b Trial of Telaglenastat (CB-839) HCI in Combination With Radiation Therapy and Temozolomide in Patients With IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma
Latest Information Update: 19 Nov 2024
At a glance
- Drugs Telaglenastat (Primary) ; Temozolomide (Primary)
- Indications Anaplastic astrocytoma
- Focus Adverse reactions
- 15 Nov 2024 Planned End Date changed from 5 Dec 2024 to 31 Dec 2025.
- 15 Nov 2024 Planned primary completion date changed from 5 Dec 2024 to 31 Dec 2025.
- 07 Dec 2023 Planned End Date changed from 5 Dec 2023 to 5 Dec 2024.